APLS NASDAQ
Apellis Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.4%
3M: +89.1%
YTD: +58.7%
1Y: +145.7%
3Y: -55.1%
5Y: -9.1%
$41.03
Last traded 2026-05-15 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2023-02-24
Earliest Filing
2026-03-31
Latest Filing
acquirer: 2
customer: 2
partner: 1
Counterparties (Filed by APLS)
5 relationshipsCompanies named in APLS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Biogen Inc. | BIIB | acquirer | Parent company entering Agreement and Plan of Merger to acquire Apellis Pharmaceuticals, Inc. | 2026-03-31 | View |
| Aspen Purchaser Sub, Inc. | ASPU | acquirer | Direct wholly owned subsidiary of Biogen Inc. entering Agreement and Plan of Merger to acquire Apellis Pharmaceuticals, | 2026-03-31 | View |
| Swedish Orphan Biovitrum AB (Publ) | — | partner | Entered into a Royalty Buy-Down Agreement to reduce royalty obligations under the existing Collaboration Agreement. | 2025-07-01 | View |
| SFJ Pharmaceuticals | — | customer | Counterparty whose development liability obligations were bought out by the Company | 2024-05-14 | View |
| Swedish Orphan Biovitrum AB | — | customer | Provider of committed development reimbursement payments | 2023-02-24 | View |
Mentioned As Counterparty
1 mentionsOther companies that named APLS in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-05-14 | Material Agreement; Termination of Agreement; Acquisition/Disposition; Delisting Notice; Change in C | Agreement Acquisition | View |
| 2026-05-04 | Officer/Director Change | View | |
| 2026-03-31 | Material Agreement; Officer/Director Change; Other Events; Exhibits | Agreement | View |
| 2026-03-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-01 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-06-04 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-04-21 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2024-08-08 | Other Events | View | |
| 2024-06-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-05-14 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2024-02-27 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-01-22 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-01-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-12-14 | Other Events | View | |
| 2023-12-01 | Regulation FD Disclosure | View | |
| 2023-10-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-08-22 | Other Events | View | |
| 2023-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR